- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04516070
Stereotactic Radiosurgery for the Treatment of Patients With Small Cell Lung Cancer Brain Metastasis
Stereotactic Radiosurgery (SRS) as Definitive Management for a Limited Number of Small Cell Lung Cancer (SCLC) Brain Metastasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To estimate the cognitive decline rate at 3 months.
SECONDARY OBJECTIVES:
I. To examine cognitive decline rate on each individual cognitive test at each time point.
II. To examine cognitive decline rates using reliable change index methodology. III. To report the overall survival of patients (death due to any cause) of patients receiving stereotactic radiosurgery (SRS) for small cell lung cancer (SCLC) brain metastasis.
IV. To report rates of local tumor control (of the treated lesions) in the brain post-treatment, as dictated by magnetic resonance imaging (MRI) surveillance schedule above.
V. To report distant tumor control in the brain (of non-treated lesions) post-treatment, as dictated by MRI surveillance schedule above.
VI. To report time elapsed from SRS to whole brain radiation therapy (WBRT). VII. To report rate of intracranial toxicity of SRS in the setting of prior WBRT.
VIII. To report rates of intracranial toxicity of concurrent atezolizumab with SRS.
IX. To determine rates of systemic and intracranial disease control (time to progression) in those who are treated concurrently with atezolizumab and SRS.
X. To determine the rates of SCLC-specific survival. XI. To assess the pre-treatment factors and baseline characteristics in the predictive determination of local control, intracranial control, systemic control, and neurocognitive outcomes.
XII. To assess the correlation between number of lesions and total volume of intracranial disease and neurocognitive outcome.
XIII. To document post-treatment intracranial toxicity profile in patients after SRS.
CORRELATIVE OBJECTIVE:
I. Cerebral spinal fluid (CSF) biomarkers.
OUTLINE:
Patients undergo SRS in the absence of disease progression or unacceptable toxicity. Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.
After completion of study treatment, patients are followed up at 1, 3, 6, 9, 12, 16, 20, 24, 30, and 36 months after SRS.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Jing Li
- Phone Number: 713-563-2300
- Email: jing.li@mdanderson.org
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77030
- M D Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have Eastern Cooperative Oncology Group (ECOG) =< 3
- All patients must have histologic evidence suggesting small cell lung cancer. Histologic confirmation may be from the primary tumor site, or from another metastatic site (systemic lymph node, etc.). Cytology-alone is not an acceptable method of diagnosis.
- Patient has 10 or less brain metastases on contrast-enhanced brain MRI scan obtained no greater than 6 weeks prior to study registration. Biopsy of brain metastasis is not required. A patient may be enrolled with zero brain metastasis assuming that the SRS is to be directed at the post-operative surgical cavity of a resected metastasis.
- Patients must be eligible to have all lesions treated with stereotactic radiosurgery as determined by the study radiation oncologist
- Patients must sign informed consent indicating that they are aware of the investigational nature of this study in keeping with the policies of the hospital
- Patients should have normal coagulation [International Normalized Ratio (INR) < 1.3]. within 28 days of enrollment.
- Patient's primary language is English
- No prior radiation therapy to the brain, including WBRT, PCI, or SRS
- Performance Status Assessment
- Standard ECOG performance status assessment will be used and determined by the treating physician
Exclusion Criteria:
- Patients are excluded if they have a history of metastatic cancer in addition to small cell malignancy or a history of uncontrolled non-metastatic cancer. Patients with localized squamous cell carcinoma and/or basal cell carcinoma are not excluded
- Patients are excluded if there is radiographic evidence of leptomeningeal disease
- Patients are excluded if there are malignant cells identified in the CSF on cytologic examination
- Patients are not excluded for circulating tumor deoxyribonucleic acid (DNA) (ctDNA) found in the CSF
- Female patients of childbearing age are excluded if they are pregnant as determined with a urine or serum beta human chorionic gonadotropin (HCG) no greater than 14 days prior to study registration, or breast-feeding
- Patients are excluded if they are unable to obtain an MRI scan for any other reason, including gadolinium allergy
- Patients are excluded with medical history of a psychiatric or neurologic illness, or other comorbidities believed to affect cognitive function. Subjects with neurocognitive deficit related to brain metastasis are an exception to this criterion and may qualify for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (SRS)
Patients undergo SRS in the absence of disease progression or unacceptable toxicity.
Patients whose disease progresses may be treated with additional courses of SRS per physician discretion.
|
Ancillary studies
Undergo SRS
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive decline
Time Frame: At 3 months post-stereotactic radiosurgery (SRS)
|
Will be defined as a decline of >= 1 standard deviation from baseline on at least 1 of the 5 cognitive tests.
Will be estimated along with the 95% confidence interval.
For patients with or without prior radiation therapy to the central nervous system, the cognitive decline rate will also be estimated respectively.
Fisher exact test will be used to compare the neurocognitive decline rate at 3 month post-SRS in subgroups (e.g.
prior therapy difference).
|
At 3 months post-stereotactic radiosurgery (SRS)
|
Incidence of adverse events
Time Frame: Up to 36 months
|
All toxicities will be assessed with National Cancer Institute predefined Common Terminology Criteria for Adverse Events version 5.
|
Up to 36 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cognitive decline
Time Frame: Up to 36 months
|
Will use descriptive statistics and boxplots to summarize and illustrate the neurocognitive function score at each assessment time.
|
Up to 36 months
|
Change in neurocognitive score
Time Frame: Baseline, up to 36 months
|
Will summarize and illustrate the change from baseline in neurocognitive score.
Will also model the cognitive data with mixed effects regression including baseline neurocognitive scores, time, and number of lesions, extra-cranial disease, and a patient specific random effect.
|
Baseline, up to 36 months
|
Overall survival
Time Frame: Time from SRS until death or last follow-up, assessed up to 36 months
|
Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g.
prior radiation treatment status).
Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.
|
Time from SRS until death or last follow-up, assessed up to 36 months
|
Small cell lung cancer (SCLC)-specific survival
Time Frame: Time from SRS till SCLC-related death or last follow-up, assessed up to 36 months
|
Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g.
prior radiation treatment status).
Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.
|
Time from SRS till SCLC-related death or last follow-up, assessed up to 36 months
|
Time to neurocognitive decline
Time Frame: Time from date of SRS till the cognitive decline, assessed up to 36 months
|
Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g.
prior radiation treatment status).
Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.
|
Time from date of SRS till the cognitive decline, assessed up to 36 months
|
Time duration from SRS to whole brain radiation therapy (WBRT)
Time Frame: Time from SRS to the start of WBRT treatment, assessed up to 36 months
|
Will be estimated using the product-limit estimator of Kaplan and Meier, and log-rank test will be used for comparison of neurocognitive decline rate in subgroups (e.g.
prior radiation treatment status).
Cox proportional hazards regression will be used to model time to event survival as a function of age, performance status, extra-cranial disease, and other factors.
|
Time from SRS to the start of WBRT treatment, assessed up to 36 months
|
Local tumor control rates
Time Frame: Up to 36 months
|
Will be estimated along with 95% confidence intervals.
The association between the control rate and patient characteristics including pre-treatment factors (e.g.
number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test.
Logistic regression will be used to assess different patient clinical factor effect on the control rate.
|
Up to 36 months
|
Distant tumor control rate
Time Frame: Up to 36 months
|
Will be estimated along with 95% confidence intervals.
The association between the control rate and patient characteristics including pre-treatment factors (e.g.
number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test.
Logistic regression will be used to assess different patient clinical factor effect on the control rate.
|
Up to 36 months
|
Rate of systemic and intracranial disease control rate
Time Frame: Up to 36 months
|
Will be estimated along with 95% confidence intervals.
The association between the control rate and patient characteristics including pre-treatment factors (e.g.
number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test.
Logistic regression will be used to assess different patient clinical factor effect on the control rate.
|
Up to 36 months
|
Response to SRS therapy
Time Frame: Up to 36 months
|
Will be determined by the radiology report.
Will be estimated along with 95% confidence intervals.
The association between the control rate and patient characteristics including pre-treatment factors (e.g.
number of lesions) will be evaluated using Wilcoxon rank sum test or Fisher exact test.
Logistic regression will be used to assess different patient clinical factor effect on the control rate.
|
Up to 36 months
|
Post-treatment intracranial toxicity profile
Time Frame: Up to 36 months
|
Will be summarized and documented.
|
Up to 36 months
|
Rate of intracranial toxicity of SRS in the setting of prior WBRT
Time Frame: Up to 36 months
|
Will be summarized according to intensity and treatment relationship, and categorized by System Organ Class.
|
Up to 36 months
|
Rate of intracranial toxicity concurrent atezolizumab with SRS
Time Frame: Up to 36 months
|
Will be summarized according to intensity and treatment relationship, and categorized by System Organ Class.
|
Up to 36 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jing Li, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Lung Diseases
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neoplasms
- Lung Neoplasms
- Small Cell Lung Carcinoma
- Brain Neoplasms
- Carcinoma, Small Cell
Other Study ID Numbers
- 2019-0900 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-05720 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IVA Lung Cancer AJCC v8
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingStage III Uterine Corpus Cancer AJCC v8 | Stage IVA Uterine Corpus Cancer AJCC v8 | Malignant Female Reproductive System Neoplasm | Stage I Cervical Cancer AJCC v8 | Stage IA Cervical Cancer AJCC v8 | Stage IA1 Cervical Cancer AJCC v8 | Stage IA2 Cervical Cancer AJCC v8 | Stage IB Cervical Cancer... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Malignant Female... and other conditionsUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; NovoCure Ltd.TerminatedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Extensive Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)Active, not recruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States, Puerto Rico
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colon Adenocarcinoma | Metastatic Colorectal Carcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IIIA Colon Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Colon Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC... and other conditionsUnited States
-
Roswell Park Cancer InstituteRecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage IIIC Lung Cancer AJCC v8 | Positive Surgical Margin | Resected MassUnited States
Clinical Trials on Questionnaire Administration
-
Fondazione Don Carlo Gnocchi OnlusUnknown
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Istanbul Aydın UniversityCompleted
-
Hospital Clínico Universitario de ValladolidRed Centinela Sanitaria de Castilla y León (RCSCYL); Centro Nacional de Gripe... and other collaboratorsRecruitingMigraine | Headache Disorders | Viral Infection | Influenza -Like Illness | Head PainSpain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | COVID-19 Infection | Hereditary Breast CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingAdvanced Malignant Solid Neoplasm | Recurrent Lymphoma | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Recurrent Plasma Cell Myeloma | Caregiver | Recurrent LeukemiaUnited States
-
I.M. Sechenov First Moscow State Medical UniversityAgency of Social Information St. PetersburgActive, not recruiting
-
I.M. Sechenov First Moscow State Medical UniversityActive, not recruitingShoulder ArthropathyRussian Federation
-
Karolinska University HospitalSahlgrenska University Hospital, Sweden; University Hospital, Linkoeping; Skane...Active, not recruitingQuality of Life | Vulvar CancerSweden